Trial Profile
An Open-label, Parallel Group, Single-sequence Study to Evaluate Pharmacokinetics, Safety, and Tolerability of a Single Dose Administration of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2015
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension; Renal failure
- Focus Pharmacokinetics
- Sponsors Novartis
- 14 Apr 2015 New trial record